Paclitaxel

For research use only. Not for use in humans.

製品コードS1150 別名：NSC 125973

分子量(MW)：853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 17100	あり
10mg	JPY 13600	あり
50mg	JPY 46800	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(125)

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

ターゲット

Microtubule (human endothelial cells) ^[1]

0.1 pM

体外試験

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
TE-15	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzqOoxKSzVyPUCuNFAxOjh5IN88US=>	NHvqRpVUSU6JRWK=
LC-2-ad	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVy0Z5p3UUN3ME2wMlAxODNzNzFOwG0>	MoPoV2FPT0WU
RL95-2	NGfIZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1G0dGlEPTB;MD6wNFA3PjhizszN	MVnTRW5ITVJ?
MZ1-PC	NW\sW3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTSTWM2OD1yLkCwNFczQSEQvF2=	MoO5V2FPT0WU
TE-8	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v6cGlEPTB;MD6wNFEyPyEQvF2=	Mo\1V2FPT0WU
SW954	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT5b5EzUUN3ME2wMlAxOTF7IN88US=>	M3zJenNCVkeHUh?=
TE-11	NUm0UGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn1TWM2OD1yLkCwNVI{KM7:TR?=	NWHR[nV[W0GQR1XS
PSN1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jTcmlEPTB;MD6wNFE{KM7:TR?=	MYHTRW5ITVJ?
MOLT-4	NHPseWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMECxOFkh\|ryP	NHezfYhUSU6JRWK=
697	NYGycpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XobmlEPTB;MD6wNFE2KM7:TR?=	MkfvV2FPT0WU
ETK-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInt[HlKSzVyPUCuNFAyPTJizszN	MWHTRW5ITVJ?
TE-10	NH[xOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGxcFVlUUN3ME2wMlAxOTV2IN88US=>	NF[1WpZUSU6JRWK=
HUTU-80	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXSwTGpkUUN3ME2wMlAxOTZ6IN88US=>	NFLBeYJUSU6JRWK=
NTERA-S-cl-D1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDibFlRUUN3ME2wMlAxOjB7IN88US=>	NXW0d4RPW0GQR1XS
MFH-ino	MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMECyOlgh\|ryP	M4P6OHNCVkeHUh?=
IA-LM	NWnlU4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTlTWM2OD1yLkCwNlgh\|ryP	MmTiV2FPT0WU
MC116	NFvzSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoezTWM2OD1yLkCwNlg6KM7:TR?=	M4DRbnNCVkeHUh?=
RKO	NWXyRXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e0NWlEPTB;MD6wNFI6QCEQvF2=	M3jKV3NCVkeHUh?=
MRK-nu-1	NVPIVlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMECyPVkh\|ryP	MXzTRW5ITVJ?
VA-ES-BJ	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYThXZZOUUN3ME2wMlAxOyEQvF2=	NEHqe2NUSU6JRWK=
KALS-1	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC0NZhKSzVyPUCuNFA{ODhizszN	NFvlcXlUSU6JRWK=
BB30-HNC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfZ[HNFUUN3ME2wMlAxOzF2IN88US=>	MVrTRW5ITVJ?
ACN	NUfqUY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3vNZZKSzVyPUCuNFA{OTZizszN	NIrnbJdUSU6JRWK=
TE-9	NH7XbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHOVW5KSzVyPUCuNFA{OjZizszN	M4\seXNCVkeHUh?=
SIG-M5	NYTYTVBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLOTWM2OD1yLkCwN\|I4KM7:TR?=	MlPsV2FPT0WU
no-10	NYjESJBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjYXJI3UUN3ME2wMlAxOzZ{IN88US=>	Ml;HV2FPT0WU
EW-1	M1P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLQTWM2OD1yLkCwN\|cyKM7:TR?=	Mo\0V2FPT0WU
SK-LMS-1	NIj6T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEC0NFEh\|ryP	NVvSdWpnW0GQR1XS
GT3TKB	NFGyfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTwTWM2OD1yLkCwOFM1KM7:TR?=	NWjzZpRyW0GQR1XS
ES4	NH[yUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf0R\|BKSzVyPUCuNFA1PDlizszN	MVPTRW5ITVJ?
IMR-5	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TKZmlEPTB;MD6wNFQ2KM7:TR?=	M{O4WnNCVkeHUh?=
NCI-H1648	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3lTWM2OD1yLkCwOFY6KM7:TR?=	NEPXU2lUSU6JRWK=
MV-4-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzFT2VKSzVyPUCuNFA1PzVizszN	NGr2UFlUSU6JRWK=
SK-UT-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMEC0PEDPxE1?	M1ewSHNCVkeHUh?=
NB13	NXLRTYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rRU2lEPTB;MD6wNFQ6OSEQvF2=	M3;qO3NCVkeHUh?=
DJM-1	NYrCSpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DteGlEPTB;MD6wNFU{KM7:TR?=	NYDCWGlQW0GQR1XS
ES8	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEC1N\|gh\|ryP	MYHTRW5ITVJ?
TE-6	M4PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXXT2pKSzVyPUCuNFA2PyEQvF2=	NWLVWmNuW0GQR1XS
KS-1	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfGTWM2OD1yLkCwOVgzKM7:TR?=	MofDV2FPT0WU
TE-1	NHPZTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEC2NFYh\|ryP	NVqx[mtbW0GQR1XS
ATN-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTuTWM2OD1yLkCwOlA6KM7:TR?=	NWjOUJd5W0GQR1XS
A4-Fuk	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7nTWM2OD1yLkCwOlEyKM7:TR?=	MXrTRW5ITVJ?
ALL-PO	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEC2N{DPxE1?	M{\CdXNCVkeHUh?=
BE-13	NHnGbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP4TWM2OD1yLkCwOlM3KM7:TR?=	NXjRUmxxW0GQR1XS
KM12	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLkVmlOUUN3ME2wMlAxPjN5IN88US=>	MoHkV2FPT0WU
NOS-1	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMEC2OUDPxE1?	NFTvdmtUSU6JRWK=
SW962	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLwTWM2OD1yLkCwOlYzKM7:TR?=	MkixV2FPT0WU
OCUB-M	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7MdGZ5UUN3ME2wMlAxPjZ{IN88US=>	NF70d4FUSU6JRWK=
NCI-H510A	M4ra[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DObGlEPTB;MD6wNFY3PSEQvF2=	MnL4V2FPT0WU
EW-16	M3PYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XNbGlEPTB;MD6wNFY6PCEQvF2=	NFT0cZpUSU6JRWK=
KGN	NWHmO2VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPsSJRKSzVyPUCuNFA4OTJizszN	MofBV2FPT0WU
LS-411N	NXXPSXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7Wc5M6UUN3ME2wMlAxPzF5IN88US=>	MnuxV2FPT0WU
Becker	NGXVZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLPTWM2OD1yLkCwO\|Ih\|ryP	MV3TRW5ITVJ?
HC-1	NULXN2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H1dmlEPTB;MD6wNFczOSEQvF2=	NGD6e4xUSU6JRWK=
CESS	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PZPWlEPTB;MD6wNFc{PyEQvF2=	NF\lT4VUSU6JRWK=
KURAMOCHI	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\yTWM2OD1yLkCwO\|Q5KM7:TR?=	M{PhWXNCVkeHUh?=
TGBC24TKB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwMEC3OVIh\|ryP	M{XrTnNCVkeHUh?=
SW982	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEC3OlYh\|ryP	MomwV2FPT0WU
HCE-4	NGLBUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[2TWM2OD1yLkCwO\|Y4KM7:TR?=	MWHTRW5ITVJ?
LOUCY	NX;MOpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzNTWM2OD1yLkCwO\|c2KM7:TR?=	MVHTRW5ITVJ?
8-MG-BA	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEC3PVYh\|ryP	NGrNRolUSU6JRWK=
HT-144	M{TENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPt[pVUUUN3ME2wMlAxQCEQvF2=	NYLB[FFyW0GQR1XS
LXF-289	NYLR[JV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEC4NVgh\|ryP	MXjTRW5ITVJ?
RS4-11	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEC4N\|Yh\|ryP	MWfTRW5ITVJ?
DEL	NIW0SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO0TWM2OD1yLkCwPFQ2KM7:TR?=	NYrHeHVbW0GQR1XS
OCI-AML2	M1PPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkf6TWM2OD1yLkCwPFUzKM7:TR?=	NYX0SJRbW0GQR1XS
CCRF-CEM	NVLNbZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHkTWM2OD1yLkCwPFcyKM7:TR?=	NI\n[oJUSU6JRWK=
A388	NGfVTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\K[mlEPTB;MD6wNFg4PCEQvF2=	MUTTRW5ITVJ?
KNS-42	M2W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEC4PVEh\|ryP	MVvTRW5ITVJ?
OVCAR-4	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEC5NFQh\|ryP	MnvKV2FPT0WU
NCI-H1355	NGPS[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\UWVFKSzVyPUCuNFA6OTRizszN	M165VXNCVkeHUh?=
BL-70	M1fKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHJVWFqUUN3ME2wMlAxQTNizszN	MYfTRW5ITVJ?
BL-41	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEC5N\|Qh\|ryP	M3TOfnNCVkeHUh?=
A101D	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHt[GRrUUN3ME2wMlAxQTZizszN	M2XiVHNCVkeHUh?=
HL-60	NY\6SZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDyTWM2OD1yLkCwPVY3KM7:TR?=	NHflT\|dUSU6JRWK=
COR-L279	M2m1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEC5PVkh\|ryP	MkCwV2FPT0WU
NCI-SNU-16	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rKXmlEPTB;MD6wNVAxQCEQvF2=	MVXTRW5ITVJ?
Calu-6	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TQ[2lEPTB;MD6wNVAyOiEQvF2=	Mm\6V2FPT0WU
SR	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnz[GhKSzVyPUCuNFExOjZizszN	NF7Mb\|dUSU6JRWK=
QIMR-WIL	M{SzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlO5TWM2OD1yLkCxNFM{KM7:TR?=	NXTDbG4yW0GQR1XS
LB647-SCLC	NUPwdlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHr3c\|lKSzVyPUCuNFExPTFizszN	NY\4UZRkW0GQR1XS
RPMI-8226	NGTHTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jySGlEPTB;MD6wNVExOiEQvF2=	M{\ucXNCVkeHUh?=
SK-PN-DW	M1Gxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XHXmlEPTB;MD6wNVEyOiEQvF2=	M4Kwe3NCVkeHUh?=
SF268	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEGxOVEh\|ryP	MnqyV2FPT0WU
HD-MY-Z	NXfGWnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XNbGlEPTB;MD6wNVE3OyEQvF2=	M4DnS3NCVkeHUh?=
DOHH-2	M4jRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSzRo1XUUN3ME2wMlAyOjB\|IN88US=>	MmrsV2FPT0WU
SCC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEGyNFQh\|ryP	NWfiTohrW0GQR1XS
ST486	NH7ONZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zpcGlEPTB;MD6wNVIxPCEQvF2=	MWjTRW5ITVJ?
NALM-6	MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPUeG1jUUN3ME2wMlAyOjF2IN88US=>	M4exUnNCVkeHUh?=
NCI-H1436	M{H4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfzXXJKSzVyPUCuNFEzOzFizszN	NGLuNIRUSU6JRWK=
KE-37	M4PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H0XmlEPTB;MD6wNVI{PCEQvF2=	M2LPWXNCVkeHUh?=
RPMI-8402	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n3dmlEPTB;MD6wNVI2PiEQvF2=	MUjTRW5ITVJ?
RXF393	NXjzOlFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv1[25KSzVyPUCuNFEzPTdizszN	NVzwOJpxW0GQR1XS
KARPAS-45	NH\IbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEGyO{DPxE1?	MWrTRW5ITVJ?
HOP-62	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXwUWZKSzVyPUCuNFEzPzZizszN	NX2yXIZNW0GQR1XS
ES1	NHPHd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO2dG5xUUN3ME2wMlAyOjh6IN88US=>	NGTrSmtUSU6JRWK=
L-363	NHTLTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly1TWM2OD1yLkCxN\|UyKM7:TR?=	NUjoSm1vW0GQR1XS
GI-1	NUjSVXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwMEGzO\|Mh\|ryP	M3XaRXNCVkeHUh?=
CTV-1	NXntc5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrIVIppUUN3ME2wMlAyPDd6IN88US=>	NV7aU4hyW0GQR1XS
TE-5	M2\PTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj0TWM2OD1yLkCxOFk3KM7:TR?=	MlPLV2FPT0WU
SNU-C2B	NUnrXXliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HDcGlEPTB;MD6wNVQ6PiEQvF2=	M4LFeHNCVkeHUh?=
K-562	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj0TWM2OD1yLkCxOVE3KM7:TR?=	NIq3S3JUSU6JRWK=
SNB75	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMEG1OEDPxE1?	NYDW[W1mW0GQR1XS
MOLT-13	NITvVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEG2N\|ch\|ryP	NH3SR5dUSU6JRWK=
LS-123	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHkWFFKSzVyPUCuNFE3PjRizszN	MoTyV2FPT0WU
NCI-SNU-5	NIezcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEG3NFEh\|ryP	M3fmdHNCVkeHUh?=
Daudi	NGrtdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\OTWM2OD1yLkCxO\|A5KM7:TR?=	M2PtbnNCVkeHUh?=
A253	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLGO3VwUUN3ME2wMlAyPzN6IN88US=>	M3G5PHNCVkeHUh?=
TGBC1TKB	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGH4d3NKSzVyPUCuNFE4PTJizszN	MoDyV2FPT0WU
SJSA-1	M3ezbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rWU2lEPTB;MD6wNVc3PyEQvF2=	NVXjfHVHW0GQR1XS
NCCIT	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r3UGlEPTB;MD6wNVc3QSEQvF2=	NUH2VIdOW0GQR1XS
NCI-H69	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PnNGlEPTB;MD6wNVc4QCEQvF2=	MnzkV2FPT0WU
SH-4	NGfweI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHDTWM2OD1yLkCxPFk2KM7:TR?=	M2rJW3NCVkeHUh?=
HCC1187	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHS[Ys4UUN3ME2wMlAyQTJ2IN88US=>	M1jTPXNCVkeHUh?=
HCC1599	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrCU5p6UUN3ME2wMlAzODJizszN	M2fsTHNCVkeHUh?=
ONS-76	NH\CNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMEKwN\|Yh\|ryP	M4L2UnNCVkeHUh?=
KU812	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7vRXE4UUN3ME2wMlAzODN7IN88US=>	MnTUV2FPT0WU
ML-2	NGLYNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmftTWM2OD1yLkCyNFQ4KM7:TR?=	M2XYfHNCVkeHUh?=
HCE-T	NVfm[WRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO2XZFFUUN3ME2wMlAzODl{IN88US=>	MmO1V2FPT0WU
NCI-H446	NFLnSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHZTWM2OD1yLkCyNVEzKM7:TR?=	MUfTRW5ITVJ?
RPMI-6666	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnaeo1uUUN3ME2wMlAzOTR7IN88US=>	MXfTRW5ITVJ?
MOLT-16	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrRTHdKSzVyPUCuNFIyPTNizszN	MnHuV2FPT0WU
JiyoyeP-2003	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW3UIlKSzVyPUCuNFIyPzZizszN	MYXTRW5ITVJ?
MHH-PREB-1	NF3uPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMEKxPVEh\|ryP	NFnWeVJUSU6JRWK=
MC-CAR	NXXKNFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\xTWM2OD1yLkCyN\|I3KM7:TR?=	MmfaV2FPT0WU
BC-3	NXTVO5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnTdYVHUUN3ME2wMlAzOzR2IN88US=>	MUDTRW5ITVJ?
KINGS-1	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvLXXVKSzVyPUCuNFI{PTVizszN	NV6zRmNzW0GQR1XS
PF-382	M4\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEKzO\|gh\|ryP	NFjyfmJUSU6JRWK=
J-RT3-T3-5	NX3He\|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXGTFhKSzVyPUCuNFI{QDNizszN	M1LWNHNCVkeHUh?=
SF539	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrYW5U{UUN3ME2wMlAzPDBzIN88US=>	MkLUV2FPT0WU
LB831-BLC	NE\IOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TTb2lEPTB;MD6wNlQ5PSEQvF2=	M17WSnNCVkeHUh?=
DMS-114	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\xUmlEPTB;MD6wNlUxOiEQvF2=	MV7TRW5ITVJ?
LB1047-RCC	NYjhV3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT3TWM2OD1yLkCyOVEh\|ryP	NYG3UHRyW0GQR1XS
LB771-HNC	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDuTWM2OD1yLkCyOVM1KM7:TR?=	NFW2[WpUSU6JRWK=
BB65-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHh[m9FUUN3ME2wMlAzPTN2IN88US=>	NH;KRXhUSU6JRWK=
BV-173	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zv[2lEPTB;MD6wNlU2PCEQvF2=	MV7TRW5ITVJ?
ARH-77	NFXT[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTrTWM2OD1yLkCyOlAyKM7:TR?=	MV;TRW5ITVJ?
IST-MEL1	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HUR2lEPTB;MD6wNlYzOyEQvF2=	M{\XcHNCVkeHUh?=
NB1	NX;QN5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf2NYFzUUN3ME2wMlAzPjh5IN88US=>	NF31NYxUSU6JRWK=
EoL-1-cell	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S5d2lEPTB;MD6wNlY5QCEQvF2=	NH\lRm9USU6JRWK=
KY821	NV;ScXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLNVVlKSzVyPUCuNFI3QTdizszN	NWLL[mN5W0GQR1XS
CMK	NUS1bY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonpTWM2OD1yLkCyO\|M1KM7:TR?=	NU\Nd4t[W0GQR1XS
NCI-H2126	NVflSW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEK3Olgh\|ryP	M3rDUnNCVkeHUh?=
NCI-H526	NX2x[VVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonaTWM2OD1yLkCyPFkyKM7:TR?=	M2rjOXNCVkeHUh?=
COLO-684	NH\GcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkKwTWM2OD1yLkCyPVA5KM7:TR?=	MmDFV2FPT0WU
NCI-H747	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LIbmlEPTB;MD6wNlk{OyEQvF2=	M2PxTHNCVkeHUh?=
JAR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMEK5OFYh\|ryP	NHvRTolUSU6JRWK=
MEG-01	NUXNfYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPUblZLUUN3ME2wMlAzQTd6IN88US=>	NF7TW2pUSU6JRWK=
MONO-MAC-6	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3YTWM2OD1yLkCzNFI{KM7:TR?=	MlPZV2FPT0WU
IST-SL1	Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljRTWM2OD1yLkCzNFQzKM7:TR?=	M4PSXXNCVkeHUh?=
CPC-N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjMXGl2UUN3ME2wMlA{ODd7IN88US=>	MoXEV2FPT0WU
NCI-H1963	M16ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M336Z2lEPTB;MD6wN\|E{OSEQvF2=	NVrmU2xWW0GQR1XS
K052	M3vubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;5TmlEPTB;MD6wN\|I1PyEQvF2=	MkXBV2FPT0WU
KM-H2	NIrhcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHPTXJVUUN3ME2wMlA{OzB5IN88US=>	MnLhV2FPT0WU
TE-12	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnmcmxKSzVyPUCuNFM{ODlizszN	M1rKc3NCVkeHUh?=
TK10	NX7Od2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDqTWM2OD1yLkCzN\|U3KM7:TR?=	Ml3DV2FPT0WU
NMC-G1	NVXHPIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEO0OVIh\|ryP	NVHUPHFvW0GQR1XS
no-11	NVviPZNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVGxUJU5UUN3ME2wMlA{PDd6IN88US=>	M3zYU3NCVkeHUh?=
NCI-H524	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\NTWM2OD1yLkCzOVI6KM7:TR?=	MWnTRW5ITVJ?
MHH-CALL-2	NY\CR\|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEO1OlIh\|ryP	NGHVbJdUSU6JRWK=
GB-1	NXHoflNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnqzTWM2OD1yLkCzOkDPxE1?	M1L6VHNCVkeHUh?=
OPM-2	NVG4cWlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMEO2O\|Mh\|ryP	NUjVZ3lUW0GQR1XS
RH-1	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\IN2VLUUN3ME2wMlA{QDF7IN88US=>	NFnUOoFUSU6JRWK=
NCI-H64	NEPkO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;4VmlCUUN3ME2wMlA{QDV5IN88US=>	NWPaNmFPW0GQR1XS
EVSA-T	NETwbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEO5NlMh\|ryP	MmP2V2FPT0WU
KARPAS-299	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPHcVlKSzVyPUCuNFM6QCEQvF2=	Moe0V2FPT0WU
MZ7-mel	NFLEfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rMOGlEPTB;MD6wOFA1KM7:TR?=	MnrlV2FPT0WU
LB373-MEL-D	M1y2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXz4S3hIUUN3ME2wMlA1OTB3IN88US=>	MXTTRW5ITVJ?
HEL	NYD0ZnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMESxOEDPxE1?	MlfEV2FPT0WU
SW872	NVnSZ2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMESyNUDPxE1?	M37ZVXNCVkeHUh?=
DU-4475	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq3TWM2OD1yLkC0NlQ1KM7:TR?=	MXrTRW5ITVJ?
IST-SL2	M3rpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7HTnB1UUN3ME2wMlA1Ojd3IN88US=>	NWTMZ2Y5W0GQR1XS
NCI-H82	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDXS\|lIUUN3ME2wMlA1OzB5IN88US=>	NWLURVRDW0GQR1XS
LC4-1	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPKUXN3UUN3ME2wMlA1OzVzIN88US=>	Mn;vV2FPT0WU
HDLM-2	NH3VN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3pUHFKSzVyPUCuNFQ{QTJizszN	M1OycnNCVkeHUh?=
MMAC-SF	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DIb2lEPTB;MD6wOFU{PCEQvF2=	NI\ZZY9USU6JRWK=
L-540	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMES2N\|kh\|ryP	NFTibHpUSU6JRWK=
MZ2-MEL	M1T0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXiOHpQUUN3ME2wMlA1PzR{IN88US=>	M33aW3NCVkeHUh?=
LU-134-A	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojXTWM2OD1yLkC0O\|c{KM7:TR?=	NHrwRVJUSU6JRWK=
UACC-257	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMES4OFkh\|ryP	MXHTRW5ITVJ?
NCI-H1581	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33vUmlEPTB;MD6wOFk2OyEQvF2=	NXv0ZnBzW0GQR1XS
NB17	NYK4d5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfjTWM2OD1yLkC0PVc6KM7:TR?=	MYTTRW5ITVJ?
SBC-1	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfpTWM2OD1yLkC1NFQzKM7:TR?=	NVHvS3FQW0GQR1XS
TALL-1	NWfMTI53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rB[2lEPTB;MD6wOVA1PSEQvF2=	M1m0dnNCVkeHUh?=
NCI-H1304	NITXVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLHOoFbUUN3ME2wMlA2OjB6IN88US=>	Ml;6V2FPT0WU
NEC8	M3\MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Hl[mlEPTB;MD6wOVI5PiEQvF2=	NGHPS4FUSU6JRWK=
CAL-148	M3GyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETleFlKSzVyPUCuNFU1OzlizszN	M2XafHNCVkeHUh?=
CGTH-W-1	M1XEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7FTWM2OD1yLkC1OFQ6KM7:TR?=	MXXTRW5ITVJ?
NCI-H889	M4Hpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP1UIFKSzVyPUCuNFU2QTJizszN	NETtTYZUSU6JRWK=
GR-ST	MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYH6e3N7UUN3ME2wMlA2PjJzIN88US=>	M1PGeHNCVkeHUh?=
KARPAS-422	NHzS[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvrTWM2OD1yLkC1OlUh\|ryP	MVPTRW5ITVJ?
RPMI-8866	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\KN2lEPTB;MD6wOVcyOiEQvF2=	NU\LTpdEW0GQR1XS
SCLC-21H	M163WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfETWM2OD1yLkC1PFg1KM7:TR?=	NH\ZSlVUSU6JRWK=
COR-L88	NGjIbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX76O\|FlUUN3ME2wMlA2QTJ5IN88US=>	NXfYbIF7W0GQR1XS
LU-139	NYHlNFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEW5PFYh\|ryP	MU\TRW5ITVJ?
SF126	M4rjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXpVIRKSzVyPUCuNFYyOzNizszN	MV3TRW5ITVJ?
NCI-H1882	NUDEXXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTwXlUzUUN3ME2wMlA3PDJ2IN88US=>	M3jRcnNCVkeHUh?=
EW-24	NFjaPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fiNWlEPTB;MD6wOlQ5OyEQvF2=	NWj1dlBSW0GQR1XS
CP67-MEL	M1nzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rkb2lEPTB;MD6wOlgyKM7:TR?=	M3SzUHNCVkeHUh?=
DG-75	NWPGNZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmi5TWM2OD1yLkC2PFk6KM7:TR?=	MV;TRW5ITVJ?
LOXIMVI	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP2VG9KSzVyPUCuNFcxOjhizszN	MXfTRW5ITVJ?
HH	NVT0c5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq3TWM2OD1yLkC3NVU4KM7:TR?=	NIjrNFRUSU6JRWK=
K5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2n6R2lEPTB;MD6wO\|IzPiEQvF2=	MXzTRW5ITVJ?
EC-GI-10	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfiSWZIUUN3ME2wMlA4OjV5IN88US=>	NXm1SnFqW0GQR1XS
SK-N-DZ	NXHWdotZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LlSGlEPTB;MD6wO\|MxPyEQvF2=	MXzTRW5ITVJ?
A3-KAW	NVLSTXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkftTWM2OD1yLkC3N\|UyKM7:TR?=	MVjTRW5ITVJ?
MLMA	NULrNWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTxZohKSzVyPUCuNFc1PjVizszN	Ml\HV2FPT0WU
LB996-RCC	M1\WO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEe3NFch\|ryP	NWDOPXhzW0GQR1XS
OS-RC-2	NGDCVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfxc282UUN3ME2wMlA4PzR6IN88US=>	MUPTRW5ITVJ?
CTB-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILTd3pKSzVyPUCuNFc5OSEQvF2=	M4PiO3NCVkeHUh?=
IST-MES1	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PC[GlEPTB;MD6wO\|kyOiEQvF2=	NH34c\|hUSU6JRWK=
LS-1034	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;ZTWM2OD1yLkC4NFM2KM7:TR?=	NYHaTpNQW0GQR1XS
HT	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMEiwPFYh\|ryP	MknJV2FPT0WU
NCI-H2141	NVqzNpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PsXGlEPTB;MD6wPFEh\|ryP	M3u1RXNCVkeHUh?=
LB2518-MEL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPhR\|JKSzVyPUCuNFgyPDFizszN	MnfwV2FPT0WU
GI-ME-N	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTLPVNNUUN3ME2wMlA5PDV{IN88US=>	M1XGb3NCVkeHUh?=
TGW	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\kUlNKSzVyPUCuNFg3ODdizszN	NFjp[GlUSU6JRWK=
SK-NEP-1	NV7iPXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknoTWM2OD1yLkC4OlQyKM7:TR?=	NE\zWJBUSU6JRWK=
NOMO-1	NUT2ZllDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPLbnhwUUN3ME2wMlA6Ojd3IN88US=>	MYDTRW5ITVJ?
ES6	NVW4eWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEm1PFkh\|ryP	NV\U[3NQW0GQR1XS
NCI-H209	M3:1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7z[FNiUUN3ME2wMlA6Pzh4IN88US=>	NHLUO\|RUSU6JRWK=
GAK	M{fm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fGPGlEPTB;MD6xNFE3KM7:TR?=	M{LyOXNCVkeHUh?=
BC-1	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nseGlEPTB;MD6xNFM3OSEQvF2=	M2n1T3NCVkeHUh?=
KLE	NH2zbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnTboRKSzVyPUCuNVA1PDNizszN	NEna[GJUSU6JRWK=
EW-3	M4LSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnmTWM2OD1yLkGwPVgh\|ryP	M2\jXXNCVkeHUh?=
NKM-1	M4PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrRVlRKSzVyPUCuNVEyKM7:TR?=	NGrpPWNUSU6JRWK=
D-336MG	NVnXWZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnwTWM2OD1yLkGxNlQ1KM7:TR?=	MVHTRW5ITVJ?
NB69	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL5[Zp5UUN3ME2wMlEyOzBzIN88US=>	NIP3OY5USU6JRWK=
D-263MG	NIP3TndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\3dJpKSzVyPUCuNVE4OTJizszN	NYPUWoNDW0GQR1XS
KP-N-YS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMUKyPVEh\|ryP	Mkj2V2FPT0WU
NCI-H1155	NWXh[FVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHYcFdKSzVyPUCuNVI2PThizszN	NYLqdVhsW0GQR1XS
BOKU	NIPndHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV23R\|VvUUN3ME2wMlEzPTd7IN88US=>	NXKxZoQ5W0GQR1XS
LAMA-84	NV:zV3JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXLVWlKSzVyPUCuNVI6QSEQvF2=	M1TjZ3NCVkeHUh?=
Raji	M{\EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPSTWM2OD1yLkGzNVE4KM7:TR?=	MljvV2FPT0WU
LU-65	M4q4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTzNnk{UUN3ME2wMlE{OzB5IN88US=>	Mn7JV2FPT0WU
NCI-H187	M361c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjYR28yUUN3ME2wMlE{QTJ2IN88US=>	NYG0VIFFW0GQR1XS
GCIY	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXq1[WRxUUN3ME2wMlE1QTBzIN88US=>	M1vMW3NCVkeHUh?=
NCI-H2107	NUjONYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO3d\|NKSzVyPUCuNVUxQCEQvF2=	M4nlUXNCVkeHUh?=
NCI-H1522	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjlUpJKSzVyPUCuNVUzPjZizszN	MVTTRW5ITVJ?
NB6	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL2WpZKSzVyPUCuNVU3OjNizszN	M{PJbXNCVkeHUh?=
EM-2	NIOzb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUW3NFYh\|ryP	M1vsOXNCVkeHUh?=
HCC2218	M4PJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMUW5PEDPxE1?	MVXTRW5ITVJ?
NCI-H748	NI\xb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XDO2lEPTB;MD6xOlM4PiEQvF2=	Mkj5V2FPT0WU
MS-1	M{LsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\Vb2lEPTB;MD6xOlU{PyEQvF2=	MV3TRW5ITVJ?
NB5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfUZ3lKSzVyPUCuNVY2QTdizszN	NF7GSVFUSU6JRWK=
OMC-1	NVH4WVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPyTWM2OD1yLkG2Olg5KM7:TR?=	NHT6OpVUSU6JRWK=
NCI-H345	NVrv[IRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPmUnZKSzVyPUCuNVY6OjhizszN	NEjLcnZUSU6JRWK=
L-428	Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33PUWlEPTB;MD6xOlk1PSEQvF2=	NUP0bXd4W0GQR1XS
SCH	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLWVVh7UUN3ME2wMlE5Pjh3IN88US=>	MVTTRW5ITVJ?
NCI-H1417	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMUmyNlch\|ryP	M4LJe3NCVkeHUh?=
COLO-320-HSR	NEjlc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMUm1N\|Ih\|ryP	M4PIV3NCVkeHUh?=
BT-474	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrUWGtFUUN3ME2wMlIxQDl{IN88US=>	NGjsOGZUSU6JRWK=
GDM-1	NVXxeW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMkG5O\|Eh\|ryP	NFz0dIxUSU6JRWK=
NCI-H2196	NFvFR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnXd4VuUUN3ME2wMlIzOjN3IN88US=>	NEX3e5dUSU6JRWK=
KP-N-RT-BM-1	NVXYZVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGq1WWVKSzVyPUCuNlI{PDlizszN	NITZSIVUSU6JRWK=
KNS-81-FD	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\GWmlEPTB;MD6yNlk2QCEQvF2=	M4nrbXNCVkeHUh?=
COLO-668	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMkO2O\|Uh\|ryP	M3u5V3NCVkeHUh?=
C2BBe1	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInPfWxKSzVyPUCuNlY4PDdizszN	MXjTRW5ITVJ?
Ramos-2G6-4C10	M1vCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMk[5OVQh\|ryP	NUnJVVN6W0GQR1XS
CAS-1	M13Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMkewPVYh\|ryP	M2noNHNCVkeHUh?=
GOTO	MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LocWlEPTB;MD6yO\|g6PCEQvF2=	NUXxPIdEW0GQR1XS
LP-1	NV\zbGdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMkiwOVch\|ryP	MWnTRW5ITVJ?
NCI-SNU-1	NYm2b4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC3TWM2OD1yLkK5OFIzKM7:TR?=	MofOV2FPT0WU
EB-3	M1jPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ziWWlEPTB;MD6yPVk4QSEQvF2=	NIX4bZRUSU6JRWK=
MHH-NB-11	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3SV5RCUUN3ME2wMlMxPDB{IN88US=>	M{D4[HNCVkeHUh?=
SK-N-FI	NGDC[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXpfJVKSzVyPUCuN\|E3QTJizszN	MXTTRW5ITVJ?
HCC2157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HMXmlEPTB;MD6zN\|kyOyEQvF2=	NEnheYZUSU6JRWK=
SIMA	NV3BOo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHIW4xKSzVyPUCuN\|Q2QDFizszN	MlHEV2FPT0WU
MDA-MB-134-VI	NH7sZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\Ud4VKSzVyPUCuN\|Y6OjhizszN	NV;JXmtqW0GQR1XS
NCI-H1694	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4q2VGlEPTB;MD6zO{DPxE1?	M4DyRXNCVkeHUh?=
EHEB	M1fFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrBTWM2OD1yLkO5NFg2KM7:TR?=	MVjTRW5ITVJ?
U-266	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEWySZdKSzVyPUCuN\|k5PDZizszN	M1O3N3NCVkeHUh?=
LC-1F	M3rnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXzbWdKSzVyPUCuOFM4PjVizszN	Mkn5V2FPT0WU
SHP-77	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHvTWM2OD1yLkS3PFU2KM7:TR?=	NVnPNHRwW0GQR1XS
LS-513	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7ZTWM2OD1yLkS5N\|A4KM7:TR?=	M1XES3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

体内試験

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

お薦めの試験操作（参考用のみ）

細胞試験： ^[1]	- 合併細胞株： Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs 濃度： 0.1-100 pM 反応時間： 72 hours 実験の流れ： Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (参考用のみ)
動物試験： ^[4]	- 合併動物モデル： Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors 製剤： Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. 投薬量： 20 mg/kg 投与方法： Administered via i.v. (参考用のみ)

細胞試験：

^[1]

- 合併

細胞株： Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度： 0.1-100 pM
反応時間： 72 hours
実験の流れ：
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(参考用のみ)

動物試験：

^[4]

- 合併

動物モデル： Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤： Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
投薬量： 20 mg/kg
投与方法： Administered via i.v.
(参考用のみ)

参考

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

- 合併

溶解度 (25°C)

体外	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	6mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Paclitaxel SDFをダウンロードする

分子量	853.91
化学式	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
保管	3年-20°C粉
保管	2 years-80°C in solvent
別名	NSC 125973
Smiles	CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000906	Not yet recruiting	Drug: NAB paclitaxel\|Drug: Cisplatin	Peritoneal Carcinomatosis	University Hospital Geneva	September 2019	Phase 1
NCT04046887	Not yet recruiting	Drug: Lonsurf\|Drug: Gemcitabine\|Drug: Nab-Paclitaxel	Pancreatic Cancer\|Pancreatic Ductal Adenocarcinoma	Patrick Joseph Loehrer Sr.\|Indiana University\|Taiho Oncology Inc.	August 2019	Phase 1
NCT03779464	Recruiting	Drug: S1 or Gemcitabine	Pancreatic Cancer\|Nab-paclitaxel\|Gemcitabine\|S1	Wuhan Union Hospital China	August 1 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
回答：
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
質問2：
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
回答：
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

TAI-1

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

研究分野別

製品類型

Paclitaxel

文献中Selleckの製品使用例(125)

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Paclitaxel SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技術サポート

よくある質問（FAQ）

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品